Andreas du Bois
The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients
Bachmann H, Aminossadati B, Schmalfeldt B, Burges A, Hillemanns P, Huober J, Wollschlaeger K, Sehouli J, Siffert W, Kuhlmann J, Kimmig R, du Bois A, Meier W, Wimberger P. The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients. Br J Clin Pharmacol 2015; 80:1139-48.
22.07.2015The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients
22.07.2015Br J Clin Pharmacol 2015; 80:1139-48
Bachmann Hagen Sjard, Aminossadati Behnaz, Schmalfeldt Barbara, Burges Alexander, Hillemanns Peter, Huober Jens, Wollschlaeger Kerstin, Sehouli Jalid, Siffert Winfried, Kuhlmann Jan Dominik, Kimmig Rainer, du Bois Andreas, Meier Werner, Wimberger Pauline
Response
Moebus V, Untch M, Kreienberg R, Hinke A, Runnebaum I, Nitz U, Kuhn W, Kurbacher C, Thomssen C, du Bois A, Lueck H, Huober J, Schneeweiss A, Jackisch C, AGO Breast Study Group. Response. J Natl Cancer Inst 2014; 106:djt452.
28.02.2014Response
28.02.2014J Natl Cancer Inst 2014; 106:djt452
Moebus Volker, Untch Michael, Kreienberg Rolf, Hinke Axel, Runnebaum Ingo B, Nitz Ulrike A, Kuhn Walther, Kurbacher Christian, Thomssen Christoph, du Bois Andreas, Lueck Hans-Joachim, Huober Jens, Schneeweiss Andreas, Jackisch Christian, AGO Breast Study Group
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial
Moebus V, Untch M, Kreienberg R, Hinke A, Runnebaum I, Nitz U, Kuhn W, Kurbacher C, Thomssen C, du Bois A, Lueck H, Huober J, Schneeweiss A, Jackisch C, AGO Breast Study Group. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Natl Cancer Inst 2013; 105:1018-26.
16.07.2013Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial
16.07.2013J Natl Cancer Inst 2013; 105:1018-26
Moebus Volker, Untch Michael, Kreienberg Rolf, Hinke Axel, Runnebaum Ingo B, Nitz Ulrike, Kuhn Walther, Kurbacher Christian, Thomssen Christoph, du Bois Andreas, Lueck Hans-Joachim, Huober Jens, Schneeweiss Andreas, Jackisch Christian, AGO Breast Study Group
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
Lück H, Schuster T, Wollschläger K, Untch M, Thomssen C, Eidtmann H, Stickeler E, Richter B, Hubalek M, Jackisch C, Stähler A, Beckmann M, Heilmann V, Huober J, Schrader I, Loibl S, du Bois A, von Minckwitz G. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. Breast Cancer Res Treat 2013; 139:779-87.
15.06.2013Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
15.06.2013Breast Cancer Res Treat 2013; 139:779-87
Lück Hans-Joachim, Schuster Tibor, Wollschläger Kerstin, Untch Michael, Thomssen Christoph, Eidtmann Holger, Stickeler Elmar, Richter Barbara, Hubalek Michael, Jackisch Christian, Stähler Ann, Beckmann Matthias, Heilmann Volker, Huober Jens, Schrader Iris, Loibl Sibylle, du Bois Andreas, von Minckwitz Gunter
Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV
Meier W, Burges A, Stähle A, Belau A, Schröder W, Richter B, Wimberger P, Schmalfeldt B, Canzler U, Kreienberg R, Wollschlaeger K, Huober J, Baumann K, Gropp-Meier M, Rau J, du Bois A, Sehouli J. Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV. Gynecol Oncol 2012; 126:236-40.
04.05.2012Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV
04.05.2012Gynecol Oncol 2012; 126:236-40
Meier Werner, Burges Alexander, Stähle Anne, Belau Antje, Schröder Willibald, Richter Barbara, Wimberger Pauline, Schmalfeldt Barbara, Canzler Ulrich, Kreienberg Rolf, Wollschlaeger Kerstin, Huober Jens, Baumann Klaus, Gropp-Meier Martina, Rau Jörn, du Bois Andreas, Sehouli Jalid
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy
von Minckwitz G, Zahm D, Khandan F, Hoffmann G, Gerber B, Eidtmann H, Fend F, Dietel M, Mehta K, du Bois A, Blohmer J, Müller B, Loibl S, Budczies J, Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss E, Huober J, Denkert C. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 2011; 29:2150-7.
25.04.2011Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy
25.04.2011J Clin Oncol 2011; 29:2150-7
von Minckwitz Gunter, Zahm Dirk-Michael, Khandan Fariba, Hoffmann Gerald, Gerber Bernd, Eidtmann Holger, Fend Falko, Dietel Manfred, Mehta Keyur, du Bois Andreas, Blohmer Jens Uwe, Müller Berit Maria, Loibl Sibylle, Budczies Jan, Hanusch Claus, Darb-Esfahani Silvia, Hilfrich Jörn, Weiss Erich, Huober Jens, Denkert Carsten
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
von Minckwitz G, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Müller V, Jackisch C, Hilfrich J, Mehta K, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, Fasching P, Eiermann W, Blohmer J, Costa S, Jüni P. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2010; 125:145-56.
03.11.2010Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
03.11.2010Breast Cancer Res Treat 2010; 125:145-56
von Minckwitz Gunter, Gerber Bernd, du Bois Andreas, Huober Jens, Hanusch Claus, Konecny Gottfried, Fett Werner, Stickeler Elmar, Harbeck Nadia, Müller Volkmar, Jackisch Christian, Hilfrich Jörn, Mehta Keyur, Untch Michael, Nüesch Eveline, Loibl Sibylle, Kaufmann Manfred, Kümmel Sherko, Fasching Peter A, Eiermann Wolfgang, Blohmer Jens-Uwe, Costa Serban Dan, Jüni Peter
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer
du Bois A, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Kurzeder C, Weber B, Herrstedt J, Hardy-Bessard A, Müller H, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Sehouli J. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol 2010; 28:4162-9.
23.08.2010Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer
23.08.2010J Clin Oncol 2010; 28:4162-9
du Bois Andreas, Jelic Svetislav, Pujade-Lauraine Eric, Burges Alexander, Pfisterer Jacobus, Gropp Martina, Staehle Anne, Wimberger Pauline, Jackisch Christian, Kurzeder Christian, Weber Béatrice, Herrstedt Jørn, Hardy-Bessard Anne-Claire, Müller Hans-Helge, Harter Philipp, Kristensen Gunnar, Joly Florence, Huober Jens, Avall-Lundqvist Elisabeth, Sehouli Jalid
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study
Moebus V, Konecny G, Kreienberg R, Hinke A, Runnebaum I, von Minckwitz G, Harbeck N, Huober J, Schneeweiss A, Nitz U, Kuhn W, Kurbacher C, Thomssen C, du Bois A, Lueck H, Jackisch C, Untch M. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 2010; 28:2874-80.
10.06.2010Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study
10.06.2010J Clin Oncol 2010; 28:2874-80
Moebus Volker, Konecny Gottfried E, Kreienberg Rolf, Hinke Axel, Runnebaum Ingo B, von Minckwitz Gunter, Harbeck Nadia, Huober Jens, Schneeweiss Andreas, Nitz Ulrike, Kuhn Walther, Kurbacher Christian, Thomssen Christoph, du Bois Andreas, Lueck Hans-Joachim, Jackisch Christian, Untch Michael
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study
von Minckwitz G, Kühn T, du Bois A, Blohmer J, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Hanusch C, Gerber B, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Untch M. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 2010; 28:2015-23.
22.03.2010Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study
22.03.2010J Clin Oncol 2010; 28:2015-23
von Minckwitz Gunter, Kühn Thorsten, du Bois Andreas, Blohmer Jens-Uwe, Thomssen Christoph, Dan Costa Serban, Jackisch Christian, Kaufmann Manfred, Mehta Keyur, Hanusch Claus, Gerber Bernd, Rezai Mahdi, Loibl Sibylle, Fasching Peter A, Huober Jens, Tesch Hans, Bauerfeind Ingo, Hilfrich Jörn, Eidtmann Holger, Untch Michael
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
Untch M, Kühn T, du Bois A, Blohmer J, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Hanusch C, Gerber B, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, von Minckwitz G. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010; 28:2024-31.
22.03.2010Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
22.03.2010J Clin Oncol 2010; 28:2024-31
Untch Michael, Kühn Thorsten, du Bois Andreas, Blohmer Jens-Uwe, Thomssen Christoph, Dan Costa Serban, Jackisch Christian, Kaufmann Manfred, Mehta Keyur, Hanusch Claus, Gerber Bernd, Rezai Mahdi, Loibl Sibylle, Fasching Peter A, Huober Jens, Tesch Hans, Bauerfeind Ingo, Hilfrich Jörn, Eidtmann Holger, von Minckwitz Gunter
Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data
Costa S, Tesch H, Gerber B, Baumann K, Thomssen C, Breitbach G, Ibishi S, Jackisch C, Mehta K, Weiss E, Ataseven B, Loibl S, Kaufmann M, Zahm D, Hilfrich J, Huober J, Eidtmann H, du Bois A, Blohmer J, von Minckwitz G. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010; 28:83-91.
01.01.2010Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data
01.01.2010Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010; 28:83-91
Costa Serban Dan, Tesch Hans, Gerber Bernd, Baumann Klaus H, Thomssen Christoph, Breitbach Georg Peter, Ibishi Shaip, Jackisch Christian, Mehta Keyur, Weiss Erich, Ataseven Beyhan, Loibl Sibylle, Kaufmann Manfred, Zahm Dirk-Michael, Hilfrich Jörn, Huober Jens, Eidtmann Holger, du Bois Andreas, Blohmer Jens-Uwe, von Minckwitz Gunter
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer
Chan S, Frimodt-Moller B, Vaury A, Carrasco E, Jones A, Harrison M, Antón A, Mayordomo J, Kreienberg R, du Bois A, Llombart A, Lluch A, Schneeweiss A, Tubiana-Hulin M, Delozier T, Huober J, Romieu G, Fumoleau P. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009; 27:1753-60.
10.04.2009Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer
10.04.2009Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009; 27:1753-60
Chan Stephen, Frimodt-Moller Bente, Vaury A Thareau, Carrasco Eva, Jones Alison, Harrison Mark, Antón Antonio, Mayordomo Jose Ignacio, Kreienberg Rolf, du Bois Andreas, Llombart Antonio, Lluch Ana, Schneeweiss Andreas, Tubiana-Hulin Michele, Delozier Thierry, Huober Jens, Romieu Gilles, Fumoleau Pierre
Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany
Pfisterer J, Arnold N, Burchardi N, Schmalfeldt B, Huober J, Harter P, Kommoss F, Bentz E, du Bois A, Hilpert F. Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009; 19:109-15.
01.01.2009Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany
01.01.2009International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009; 19:109-15
Pfisterer Jacobus, Arnold Norbert, Burchardi Nicole, Schmalfeldt Barbara, Huober Jens, Harter Philipp, Kommoss Friedrich, Bentz Eva-Katrin, du Bois Andreas, Hilpert Felix
Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)
Wagner U, Jackisch C, Meier W, Schmalfeldt B, Stähle A, Gropp M, Sehouli J, Lück H, Loibl S, Huober J, Pfisterer J, du Bois A, AGO Ovarian Cancer Study Group. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecologic oncology 2007; 105:132-7.
01.04.2007Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)
01.04.2007Gynecologic oncology 2007; 105:132-7
Wagner Uwe, Jackisch Christian, Meier Werner, Schmalfeldt Barbara, Stähle Anne, Gropp Martina, Sehouli Jalid, Lück Hans-Joachim, Loibl Sybille, Huober Jens, Pfisterer Jacobus, du Bois Andreas, AGO Ovarian Cancer Study Group
Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial
Harter P, Emons G, Pfisterer J, Wollschlaeger K, Meerpohl H, Breitbach G, Tanner B, Sehouli J, Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee, Schmalfeldt B, Muenstedt K, Schröder W, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, AGO Ovarian Cancer Study Group. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Annals of surgical oncology 2006; 13:1702-10.
01.12.2006Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial
01.12.2006Annals of surgical oncology 2006; 13:1702-10
Harter Philipp, Emons Guenter, Pfisterer Jacobus, Wollschlaeger Kerstin, Meerpohl Hans-Gerd, Breitbach Georg-Peter, Tanner Berno, Sehouli Jalid, Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee, Schmalfeldt Barbara, Muenstedt Karsten, Schröder Willibald, du Bois Andreas, Hahmann Maik, Hasenburg Annette, Burges Alexander, Loibl Sibylle, Gropp Martina, Huober Jens, Fink Daniel, AGO Ovarian Cancer Study Group